
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Once thought untreatable, we now have two FDA-approved medications for TD and a handful of off-label options. More in this research update.




